10-K: Aibotics 10-K: Pivot to AI Robotics and Financial Woes

Aibotics, Inc. reports a net loss of $2.2 million for 2025 while pivoting its business focus toward AI-powered robotics and wellness products.

Summary

• Reported a net loss of $2,215,751 for the fiscal year ended December 31, 2025, compared to a $1,848,275 loss in 2024.
• Generated minimal revenue of $2,183 in 2025, with no revenue reported in 2024.
• Acquired assets from Philon Labs in late 2024, shifting strategic focus to AI-powered robotics, specifically the 'Phill Robot' and 'Milkyway' storage system.
• Maintained a significant working capital deficiency of $4,564,798 as of December 31, 2025.
• Management identified material weaknesses in internal controls over financial reporting, specifically regarding segregation of duties and classification of equity instruments.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this as a highly distressed situation characterized by recurring losses, significant debt defaults, and a lack of meaningful revenue, despite the strategic pivot.

Positives

• Successfully acquired intellectual property assets from Philon Labs to diversify business operations into AI-powered consumer products.
• Increased cash and cash equivalents to $255,940 as of December 31, 2025, up from $185,097 in the prior year.
• Secured $300,000 in proceeds from convertible notes payable during 2025 to support operations.

Negatives

• Incurred a net loss of $2.2 million, reflecting continued operational challenges.
• Working capital deficiency remains severe at $4.56 million.
• Current liabilities of $4.83 million significantly exceed current assets of $0.27 million.
• The company is in default on several convertible notes payable.
• Management concluded that internal controls over financial reporting were not effective as of December 31, 2025.

Risks

• Substantial doubt exists regarding the company's ability to continue as a going concern.
• Heavy reliance on future debt or equity financing to fund ongoing operations.
• Potential for dilution of existing shareholders due to the issuance of common stock to settle liabilities and fund operations.
• Regulatory risks associated with the development of psychedelic-based therapies, despite the current pivot to robotics.
• Operational risks related to the successful commercialization of the Phill Robot and Milkyway products.

Future Outlook

The company intends to focus on integrating AI and robotics into consumer wellness products while continuing to explore psychedelic research. Future operations are heavily dependent on securing additional capital to resolve liquidity issues and fund development.

Management Comments

• Management acknowledges that conditions raise substantial doubt about the company's ability to continue as a going concern.
• The company is actively pursuing additional equity financing through discussions with investment bankers and private investors.
• Management believes the acquisition of Philon Labs assets will transform the company into a growth-oriented entity.

Industry Context

StockSavvy.ai notes that Aibotics is attempting a pivot from the high-risk, capital-intensive psychedelic research sector to the competitive consumer AI-robotics market, a move that highlights the company's struggle to find a viable, revenue-generating business model.

Comparison to Industry Standards

• The company's revenue generation is negligible compared to established players in both the biotech and consumer robotics sectors.
• The reliance on debt-for-equity swaps to settle liabilities is common among distressed micro-cap companies but indicates significant financial strain compared to industry peers.
• The lack of independent board committees (audit, compensation) is below the standard for companies seeking to maintain high corporate governance ratings.

Corporate Governance

Legal Proceedings

• The company is not currently a party to any material legal proceedings.

Related Party Transactions

• Executive Consulting Agreement with CEO Benjamin Kaplan, with significant accrued compensation outstanding.
• Note payable to a major shareholder for $165,000.

Stakeholder Impact

• Shareholders face significant dilution risk due to ongoing stock issuances for debt settlement and operations.
• Creditors face risks associated with the company's default on convertible notes.
• Employees and consultants are impacted by the company's limited cash resources.

Next Steps

• Seek additional equity financing to address liquidity issues.
• Attempt to commercialize the Phill Robot and Milkyway products.
• Address material weaknesses in internal controls over financial reporting.
• Seek stockholder approval for the 2026 Equity Incentive Plan.

Key Dates

Recommendation

The company exhibits classic signs of financial distress, including a going concern warning, default on debt, and a lack of revenue. The pivot to a new business model is speculative and does not mitigate the immediate liquidity crisis.

Keywords

Aibotics, AI robotics, psychedelics, TPIA, Philon Labs, going concern, OTC Pink